[stock_market_widget type="clock-markets" template="analog" timezone="America/New_York" title="New York" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Europe/London" title="London" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Europe/Brussels" title="Brussels" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Asia/Hong_Kong" title="Hong Kong" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Asia/Tokyo" title="Tokyo" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Australia/Sydney" title="Sydney" style="font-size: 7px; width: 100px;"]

Stock Market News

Pfizer. BioNTech seek to revoke CureVac’s patent infringement claims

09/02/2022

Less than a minute

2022.09.02 16:50

Pfizer. BioNTech seek to revoke CureVac's patent infringement claims
A vial labelled “CureVac COVID-19 Vaccine” is seen in this illustration taken January 16, 2022. REUTERS/Dado Ruvic/Illustration

(Reuters) – Pfizer (NYSE:PFE) and its German partner BioNTech have filed proceedings at the High Court of England & Wales seeking judgment that their COVID-19 vaccine, based on mRNA technology, does not infringe on CureVac’s European patents, according to a regulatory filing on Friday.

Source

09/02/2022

Less than a minute